Ionis Pharmaceuticals (IONS) EBIAT (2016 - 2025)
Historic EBIAT for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$128.6 million.
- Ionis Pharmaceuticals' EBIAT rose 845.24% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.3 million, marking a year-over-year increase of 2855.79%. This contributed to the annual value of -$453.9 million for FY2024, which is 2391.87% down from last year.
- As of Q3 2025, Ionis Pharmaceuticals' EBIAT stood at -$128.6 million, which was up 845.24% from $123.6 million recorded in Q2 2025.
- In the past 5 years, Ionis Pharmaceuticals' EBIAT ranged from a high of $224.6 million in Q4 2021 and a low of -$147.4 million during Q3 2023
- Its 5-year average for EBIAT is -$66.9 million, with a median of -$85.3 million in 2023.
- In the last 5 years, Ionis Pharmaceuticals' EBIAT plummeted by 102651.41% in 2024 and then soared by 28644.99% in 2025.
- Ionis Pharmaceuticals' EBIAT (Quarter) stood at $224.6 million in 2021, then plummeted by 123.34% to -$52.4 million in 2022, then skyrocketed by 82.33% to -$9.3 million in 2023, then crashed by 1026.51% to -$104.3 million in 2024, then decreased by 23.25% to -$128.6 million in 2025.
- Its EBIAT stands at -$128.6 million for Q3 2025, versus $123.6 million for Q2 2025 and -$146.9 million for Q1 2025.